Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes

 Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its
              Oral Insulin for the Treatment of Type 1 Diabetes

Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2
Diabetes in January

PR Newswire

JERUSALEM, Dec. 20, 2013

JERUSALEM, Dec. 20, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
(NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
focused on the development of oral drug delivery systems, announced today
successful results in a clinical trial testing the pharmacokinetic dose
response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

Patients were treated with a different dose of oral insulin at each study
visit; blood glucose and insulin levels were then monitored for the ensuing
five hours. Patient responses positively correlated with administered doses,
as did the duration of the effect.

"Based on these and the notable results from our previous oral insulin trials
in type 1 diabetes, we continue to move forward with this indication in
parallel to our advanced clinical studies in type 2 diabetes," commented CEO
Nadav Kidron.

Type 1 diabetes (T1DM) is an autoimmune disease wherein the body destroys its
own insulin-producing cells, leaving patients completely dependent on external
insulin sources. The disease, formerly known as juvenile diabetes, currently
affects both young and adult populations. According to the International
Diabetes Federation, T1DM is on the rise at a rate of 3% per year and
currently affects approximately 36 million people worldwide - about 10% of the
global diabetes population. The disease was formerly known as juvenile
diabetes, and currently affects both young and adult populations.

About ORMD-0801 Oral Insulin and T1DM

T1DM is currently treated with two types of insulin replacement therapies:
long-acting insulin (basal) to help maintain stable insulin levels during
fasting periods, and pre-meal insulin (bolus) doses. Oramed proposes to
introduce ORMD-0801 to replace the mealtime (bolus) insulin doses, which would
significantly reduce the number of daily injections. Additionally, oral
administration offers the benefit of reduced systemic exposure and may enable
tighter regulation of blood sugar levels by directly affecting glucose control
in the liver. For more information on ORMD-0801, the content of which is not
part of this press release, please visit http://oramed.com/index.php?page=14

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's Protein Oral Delivery (POD^TM) technology is
based on over 30 years of research by top research scientists
atJerusalem'sHadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on
patients with type 2 diabetes (T2DM) under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), which has been assessed in
healthy volunteers (Phase 1b) and is currently being tested in T2DM patients
(Phase 2a). Oramed is also moving forward with clinical trials of ORMD-0801
for the treatment of type 1 diabetes. The company's corporate and R&D
headquarters are based inJerusalem.

For more information, the content of which is not part of this press release,
please visit www.oramed.com

Forward-looking statements:This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our clinical trials, anticipated timeframe of trial results or
revolutionizing the treatment of diabetes with our products. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman

US: +1-718-831-2512
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Website: http://www.oramed.com
Press spacebar to pause and continue. Press esc to stop.